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Abstract
Background: Hepatitis B virus (HBV) infection is a major risk factor which can lead to development of hepatocellular
carcinoma (HCC). In this study, we aimed to explore the effects of toll-like receptor 4 (TLR4) downregulation on the
growth and survival of HBV-related HCC cells and to examine the molecular mechanisms been involved.
Methods: The expression levels of TLR4 were examined in a panel of HCC cell lines (HepG2, SMMC7721, Huh7,
HepG2.2.15 and Hep3B). The effects of TLR4 downregulation on the proliferation, apoptosis, and tumorigenicity of
HBV-related HepG2.2.15 cells were determined. The effects of TLR4 downregulation on multiple signaling pathways
were also measured. Co-immunoprecipitation and immunofluoresence staining assays were performed to investigate
the interaction between TLR4 and HBV X protein (HBx).
Results: The mRNA and protein levels of TLR4 were significantly increased in HepG2.2.15 cells than those in the other
cells which have been studied. Downregulation of TLR4 significantly decreased the proliferation and induced G2/M cell
cycle arrest and apoptosis in HepG2.2.15 cells. TLR4 depletion inhibited HepG2.2.15 cell colony formation and tumor
growth in nude mice. TLR4 silencing decreased the phosphorylation of ERK1/2 but not JNK1/2, p38, or NF-κB. Chemical
inhibition of ERK1/2 approximately phenocopied the growth-suppressive effect of TLR4 downregulation on HepG2.2.15
cells. In addition, TLR4 showed a physical interaction with HBx.
Conclusions: Taken together, TLR4 plays a tumor-promoting role in HBV-related HCC cells, which is associated with
regulation of ERK1/2 activation and interaction with HBx. Therefore, TLR4 may be a potential therapeutic target for
HBV-related HCC.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third leading cause of cancer-
related deaths worldwide [1]. In 2012, it was estimated
554,000 new HCCs cases and 521,000 deaths from HCC
in the world [2]. Chronic infection with hepatitis B virus
(HBV) is accepted as a major risk factor which can lead to
development of HCC [3]. Several HBV trans-activating
factors such as HBV X protein (HBx), PreS2 activators,
and hepatitis B spliced protein (HBSP) have been found to
be implicated in hepatocarcinogenesis [4]. HBx protein
can affect multiple cellular activities such as cell prolif-
eration, cell cycle progression, and apoptosis [5], thus
having a significant impact on the development of
HBV-induced HCC.
Toll-like receptors (TLRs) are a family of transmem-
brane signaling receptors that are abundantly expressed
on immune cells [6]. They can recognize a wide range of
pathogens such as Epstein–Barr virus, HBV, and Helico-
bacter pylori, thus playing key roles in innate immunity
[6–9]. In addition to immune cells, various types of tumor
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cells also express TLRs [10, 11]. It has been reported that
TLR4 is overexpressed in HCC, compared to surrounding
non-malignant liver tissues [12]. Compelling evidence
indicates an important role for TLR4 signaling in hepato-
cellular tumorigenesis and progression [13, 14]. For in-
stance, activation of TLR4 signaling by lipopolysaccharide
(LPS) has been documented to promote cell survival and
proliferation in HCC cells [14]. Stimulation of TLR4 usu-
ally leads to activation of multiple intracellular signaling
pathways including nuclear factor kappaB (NF-κB) and
mitogen-activated protein kinases (MAPKs) [15]. MAPKs
phosphorylate specific serines and threonines of target
protein substrates and regulate numerous biological
activities such as gene expression, mitosis, apoptosis,
and tumorigenesis [16].
Given that the importance of TLR4 signaling in tumor
development and growth, in this study we aimed to ex-
plore the effects of TLR4 activation on the growth and




HBV-unrelated HCC cell lines (HepG2, SMMC7721 and
Huh7) and HBV-related HCC cell lines (HepG2.2.15 and
Hep3B) were purchased from the Cell Bank of the Chinese
Academy of Sciences (Shanghai, China). Cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM,
Solarbio, Shanghai, China) supplemented with penicillin
(100 U/mL), streptomycin (0.1 mg/mL), and 10 % fetal
bovine serum (Gibco, Grand Island, NY, USA) in a 5 %
CO2 humidified incubator at 37 °C. G418 (6.5 mg/mL;
Solarbio, Shanghai, China) was added to the culture
medium to maintain HepG2.2.15 cells. LPS from
Escherichia coli 0111:B4 was purchased from Sigma
Aldrich (St. Louis, MO, USA). SB203580, SP600125,
and PD184352 were purchased from Selleckchem
(Houston, TX, USA) and pyrrolidine dithiocarbamate
(PDTC) from Tocris (Bristol, UK).
RNA interference
Small interfering RNAs (siRNAs) targeting TLR4 were
designed and synthesized by Ribobio (Shanghai, China).
Non-targeting siRNAs were used as negative controls
(Ribobio, Shanghai, China). Individual siRNAs (50 nM)
were transfected into cells with Lipofectamine™ 2000
Transfection Reagent (Invitrogen, MA, USA) according
to the manufacturer’s instructions. After incubation for
24 and 36 h, transfected cells were collected for analysis
of mRNA and protein expression, respectively.
Western blot analysis
Whole cell lysates were prepared using lysis buffer
[50 mmol/L Tris–HCl (pH 8.0), 150 mmol/L NaCl, 0.5 %
NP-40, 0.1 % SDS, and 5 mmol/L EDTA (pH 8.0)] con-
taining aprotinin (2 mg/L), phosphatase inhibitor Leupep-
tin (5 mg/L) and phenylmethylsulfonyl fluoride (PMSF;
1 mmol/L; Solarbio). Protein concentrations were deter-
mined using the BCA protein assay (Thermo Fisher Scien-
tific, Rockford, USA). Equal amounts of proteins were
subjected to 10 or 12 % SDS-polyacrylamide gel electro-
phoresis and transferred to polyvinylidene difluoride
membranes (Millipore, Billerica, MA, USA). The mem-
branes were blocked with 5 % fat-free milk and incubated
with primary antibodies at 4 °C overnight, followed by
incubation with secondary antibodies for 2 h. Signals were
visualized by chemiluminescence (Thermo Fisher Scien-
tific, Rockford, USA) and quantitated using Image J soft-
ware. Primary antibodies used in this study were rabbit
anti-TLR4 polyclonal antibody (1:1,500; Santa Cruz Bio-
technology, CA, USA), rabbit anti-SAPK/JNK polyclonal
antibody (1:1,000), rabbit anti-p44/42 MAPK (Erk1/2)
polyclonal antibody (1:1,000), rabbit anti-Phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) polyclonal antibody(1:1,
000), rabbit anti-p38 MAP Kinase polyclonal antibody
(1:1,000), rabbit anti-Phospho-p38 MAP Kinase (Thr180/
Tyr182) polyclonal antibody (1:1,000), rabbit anti-NF-kB
p65 polyclonal antibody (1:1,000), and rabbit anti-phospho-
NF-kB p65 (Ser536) polyclonal antibody (1:1,000) (Cell
Signaling Technology, USA), and rabbit anti-JNK1 + JNK2
(phospho T183 + Y185) polyclonal antibody(1:1,000)
(abcam, USA), and mouse anti-β-actin polyclonal anti-
body (1:1,000) (Proteintech, Wuhan, China). Anti-
rabbit (1:10,000) and anti-mouse (1:10,000) IgGs were
purchased from Proteintech (Wuhan, China).
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
Total RNA was extracted using TRIzol (Invitrogen)
and cDNA synthesis was performed using the Prime-
Script RT reagent Kit (Takara, Japan). qPCR was per-
formed using the SYBR Premix Ex Taq ™II (Takara) on
an Applied Biosystems 7300 Real-Time PCR System
(ABI, USA). The TLR4 primer sequence (PrimerBank ID:
373432602c1) came from PrimerBank (http://pga.mgh.
harvard. edu/primerbank/): sense: 5′-AGA CCT GTC
CCT GAA CCC TAT-3′; and anti-sense: 5′-CGA TGG
ACT TCTAAA CCA GCC A-3′. The primers for amplifi-
cation of GAPDH were as follows: sense: 5′-GTT GGA
GGT CGG AGT CAA CGG A-3′; and anti-sense: 5′-
GAG GGA TCT CGC TCC TGG AGG A-3′. All PCR
amplifications were performed with an initial denaturation
at 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and
62 °C for 30 s.
Cell counting kit-8 (CCK8) assay
Cells were seeded in 96-well plates at a density of 4000–
5000 cells per well. Cells were allowed to adhere for
12 h and starved with serum-free medium for additional
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12 h followed by treatment with 30 μmol/L of SB203580,
SP600125, PD184352, or PDTC. The cells were exposed
to 10 μg/mL LPS for different times. CCK8 (Zomanbio,
China) was added to each well and incubated for 1 h at
37 °C. The optical density (OD) was measured at a wave-
length of 450 nm using a microplate reader.
Flow cytometry analysis
Cells were seeded at a density of 5 × 105 cells per well in
6-well plates. After treatment, cells were fixed in ice-
cold 70 % ethanol. Cell cycle distribution was analyzed
using the Cell Cycle Analysis Kit (MultiSciences, China)
and apoptosis was detected using the Annexin V-PE/7-
AAD Apoptosis Detection Kit I (BD BioSciences, USA)
according to the manufacturer’s instruction. Stained cells
were examined by FACSCalibur flow cytometry.
Tumorigenicity in nude mice
For tumorigenicity assays, 4- to 6-week-old male BALB/
C nu/nu nude mice (16–18 g) were purchased from the
Experimental Animal Center of Shanghai (Shanghai,
China). Mice were randomly divided into 3 groups (n = 5
for each group) to receive a s. c. injection of 5 × 106
HepG2.2.15 cells transduced with replication-defective
lentivirus expressing TLR4-shRNA (Le-TLR4) or negative
control shRNA (Le-NC) or normal saline (NS). Le-NC
(2 × 107TU, 40 μL/mouse), Le-TLR4 (2 × 107TU, 40 μL/
mouse) or NS (40 μL/mouse) was injected intratumorally
at several points every two days, with an accumulated
dose of 1 × 108 TU. Tumor volumes were measured every
5 days with a caliper and calculated according to the
formula: 0.5 × length × width2. At 18 days after the cell
inoculation, mice were sacrificed. The same treatments
were done to other 3 groups of nude mice received
HepG2 cells. All experimental manipulations were under-
taken in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals, with
the approval of the Scientific Investigation Board of the
Nanchang University, Nanchang, China.
Laser scan confocal microscopy
Cells were seeded on coverslips and allowed to adhere
for 12 h. After treatment, cells were fixed with 100 %
methanol for 30 min and blocked with 5 % bovine serum
albumin (BSA) for 30 min. Coverslips were incubated
with mouse anti-HBx monoclonal antibody (1:100,
abcam) or rabbit anti-TLR4 polyclonal antibody (1:100,
Santa Cruz Biotechnology) in 1 % BSA at 4 °C over-
night, followed by with fluorescence labeled secondary
antibody (1:100, Earthox, USA) in 1 % BSA for 30 min
at room temperature. Cell nuclei were counterstained
with 4′,6-diamidino-2-phenylindole (DAPI; Sigma). Im-
ages were captured using Nikon A1 Confocal Laser
Microscope System and adjusted using NIS-Elements
Viewer 4.0 (Nikon, Japan).
Co-immunoprecipitation assay
HepG2.2.15 cells were grown on 10-cm cell dishes. After
culture for 36 h, cells were harvested and lysed in the
immunoprecipitation lysis buffer [20 mmol/L Tris–HCl
(pH 7.5), 150 mmol/L NaCl, 1 % NP-40, 0.1 % SDS, 0.01 g/
mL sodium deoxycholate, and 2 mmol/L EDTA(pH 8.0)]
containing Aprotinin (2 mg/L), Leupeptin (5 mg/L) and
PMSF (1 mmol/L). Total cell lysates were pre-cleaned with
protein-A +G Sepharose Beads (7seabiotech, China) for 3 h
at 4 °C and centrifuged. Aliquots of the supernatant were
used as input. The remaining supernatants were incubated
with mouse anti-HBx or anti-TLR4 antibody or isotype
control IgGs and then with protein A +G Sepharose Beads
(50 % slurry) at 4 °C overnight. After centrifuging, the
pellets were resuspended with the SDS sample buffer and
boiled to remove Sepharose beads. Lysate inputs and
immunoprecipitates were then subjected to SDS-PAGE
and analyzed by Western blotting. Total cell lysates were
used as input control.
Statistical analysis
Data were presented as mean and standard deviation
(SD) for normally distribution. Groups were compared
by one-way Analysis of variance (ANOVA) and multiple
comparisons by LSD-t test using SPSS 21.0 (IBM SPSS
for Windows, Version 21.0; IBM Corporation, Armonk,
NY, USA). P < 0.05 was considered significant.
Results
TLR4 is overexpressed in HBV-related HepG2.2.15 cells
We firstly examined the mRNA and protein expression
of TLR4 in a panel of HCC cells (HepG2, SMMC7721,
Huh7, HepG2.2.15 and Hep3B). As illustrated in Fig. 1a.
the TLR4 mRNA level was significantly higher in
HepG2.2.15 and SMMC7721 cells than in the other cell
lines. However, the protein level of TLR4 was signifi-
cantly greater in HepG2.2.15 and Hep3B cells than in
HepG2, SMMC7721, and Huh7 cells (Fig. 1b).
Targeted downregulation of TLR4 results in decreased
growth and enhanced apoptosis of HepG2.2.15 cells
in vitro
To explore the biological significance of TLR4 in HBV-
related HCC cells, we specifically knocked down its
expression in HepG2.2.15 cells using siRNA technology.
This cell line was chosen because of its high expression
of TLR4 both at the mRNA and protein levels. The
amounts of TLR4 mRNA and protein were significantly
reduced in cells transfected with one TLR4 siRNA
(TLR4-1), showing efficient knockdown of TLR4 (Fig. 2).
Similar results were observed in the cells transfected
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with another TLR4 siRNA (TLR4-2), with less effect of
TLR4 downregulation. However, TLR4 expression
levels were little affected by the transfection of the
TLR4-3 siRNA.
We next studied the impact of TLR4 silencing on
HepG2.2.15 cell proliferation in vitro. CCK assay
showed that downregulation of TLR4 by TLR4-1 and
TLR4-2 significantly reduced the proliferation rate of
HepG2.2.15 cells compared with control siRNA-transfected
counterparts (P < 0.05; Fig. 3a). Colony formation assay
further showed that TLR4 silencing resulted in a significant
decrease in colony formation in HepG2.2.15 cells (P < 0.05;
Fig. 3b). Cell cycle analysis revealed that TLR4 depletion
caused a significant inhibition of cell cycle progression,
leading to a selective accumulation of cells in the G2
phase compared with control siRNA transfectants (Fig. 3c).
Fig. 1 TLR4 expression levels in five hepatoma cell lines. a Graph of relative ratios of mRNA of TLR4 to GAPDH in each cell line. b Top: Protein
expression of TLR4 was examined in HepG2, SMMC7721, Huh7, HepG2.2.15 and Hep3B by western blot; and bottom: Graph of relative ratios of
protein of TLR4 to β-actin in each cell line. *P < 0.05, **P < 0.01, compared with HepG2.2.15, n = 3
Fig. 2 TLR4 expression in untreated and treated group of HepG2.2.15. a Graph of relative ratios of mRNA of TLR4 to GAPDH in each group. b Top:
Protein expression of TLR4 was examined in Normal, Control siRNA, TLR4-1, TLR4-2, TLR4-3 group by western blot; and bottom: Graph of relative
ratios of protein of TLR4 to β-actin in each group. *P < 0.05, **P < 0.01, compared with Control siRNA group, n = 3
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Quantification of apoptosis by Annexin V-PE/7-AAD
double labeling indicated that TLR4-downregulated
HepG2.2.15 cells had an about 3-4-fold increase in the
apoptotic index, compared to control siRNA-transfected
cells (Fig. 3d).
Downregulation of TLR4 retards tumor growth in vivo
To get more insight into the relevance of TLR4 silencing
in vivo, an equal number of HepG2.2.15 cells infected
with Le-TLR4 or Le-NC recombinant lentivirus were
injected s. c. into the right flank of nude mice. Com-
pared to the NS group and control group, the Le-TLR4
group showed a significant reduction in the tumor
volume (P < 0.05; Fig. 4a-c). Simultaneously, the down-
regulation of TLR4 in Le-TLR4 xenograft tumors con-
tributed to a remarkable reduction in the tumor weight
(P < 0.05; Fig. 4d). However, injection of HepG2 cells
transfected with Le-TLR4 or Le-NC recombinant lenti-
virus into nude mice did not inhibit the growth of tumor
(Fig. 4e-f ).
TLR4 signaling regulates the activation of ERK1/2 in
HepG2.2.15 cells
To investigate the molecular mechanisms involved in the
action of TLR4, we examined the activation of ERK1/2,
JNK1/2, p38, and NF-κB by TLR4 silencing. As shown in
Fig. 3 TLR4 downregulation by siRNA-mediated silencing in HepG2.2.15 cells. a Cell proliferation was assessed by the CCK assay. HepG2.2.15 cells
expressing TLR4-1 or TLR4-2 siRNAs showed a significantly reduced proliferation rate compared with those harboring TLR4-3 or scrambled control
siRNAs. b Colony numbers was assessed by colony formation assay. The quantitative analyses revealed HepG2.2.15 cells expressing indicated siRNAs
showed a significantly reduced colony formation rate compared with those harboring normal or scrambled control siRNAs. c Cell cycle distribution
was assessed by Cell Cycle Analysis Kit. HepG2.2.15 cells expressing indicated siRNAs showed a significantly increased rate in the G2 phase compared
with those harboring normal or scrambled control siRNAs. d Early apoptosis was detected by flow cytometry. Early apoptotic cells were increased in
HepG2.2.15 cells expressing indicated siRNAs compared with those harboring normal or scrambled control siRNAs. *P < 0.05, **P < 0.01, compared
with Control siRNA group, n = 3
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Fig. 5a, ERK1/2 phosphorylation was remarkably dis-
rupted in TLR4-1 transfectants relative to control siRNA-
transfected cells. In contrast, the phosphorylation levels of
JNK1/2, p38, and NF-κB were comparable between TLR4-
1-transfected and control siRNA-transfected cells. We
also examined the effect of TLR4 downregulation on the
phosphorylation of c-Fos, a well-defined effector of ERK1/
2 signaling. Notably, TLR4-downregulated cells showed a
marked decline in phosphorylated c-Fos, compared to
control siRNA-transfected cells (Fig. 5a).
To further confirm the mediating role of ERK1/2 in
TLR4 signaling, chemical inhibitors SB203580, SP600
125, PD184352 and PDTC were used to block MAPKs
and NF-κB activation, and LPS was used to stimulate
Fig. 4 Downregulation of TLR4 inhibits the growth of HepG2.2.15-derived xenografts in athymic nude mice. HepG2.2.15 transfectants expressing
replication-defective recombinant lentiviral carrying the TLR4-shRNA(Le-TLR4) or replication-defective recombinant lentiviral carrying the
negative control shRNA(Le-NC) were inoculated s.c. into immunodeficient mice. a Macrographic images of the HepG2.2.15 subcutaneous
tumor xenografts in each mouse; b The size of subcutaneous tumor xenografts from each mouse; (n = 5 per group). c Growth curves of
the tumor xenografts, volume of denuded tumor xenografts, volume of Le-TLR4 group reduced significantly compared to control shRNA
(Le-NC) group and normal saline group. d Weight of denuded tumor xenografts, weight of Le-TLR4 group reduced significantly compared
to control shRNA (Le-NC) group and normal saline group. e and f Volume and weight of tumor xenografts was not changed in nude mice
received HepG2 cells **P < 0.01, compared with Le-NC group
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TLR4 signaling. CCK assay showed that combined treat-
ment with PD184352 and LPS significantly (P < 0.05)
reduced the proliferation rate of HepG2.2.15 cells, com-
pared with those treated with LPS and SB203580,
SP600125 or PDTC (Fig. 5b).
Interaction of TLR4 and HBx
Immunofluorescence analysis revealed that TLR4 dis-
played a diffuse spotty distribution in the cytoplasm in
HepG2.2.15 cells, and HBx had a consistent cytoplas-
mic staining (Fig. 6a). To confirm the interaction
Fig. 5 TLR4 knockdown influences the expression and activation of multiple downstream genes. a Representative images of 3 independent experiments
with similar results are shown, silencing of TLR4 decreases the phosphorylation of ERK1/2 protein and c-Fos protein, a well-defined effector of ERK1/2
signaling. However, silencing of TLR4 has no impact on JNK1/2, NF-κB or p38 signaling. P< 0.05. b Chemical inhibitors SB203580, SP600125, PD184352
and PDTC were used to block MAPKs and NF-κB activation, and LPS was used to stimulate TLR4 signaling. After indicated treatments, the cell viability was
assessed at different time points using the CCK8 assay. Combined treatments with PD184352 and LPS significantly reduced the proliferation rate of
HepG2.2.15 cells, compared with those treated with LPS and SB203580, SP600125 or PDTC. P< 0.05
Fig. 6 Structural and functional interaction of TLR4 and HBx in HepG2.2.15. a Immunofluorescence analysis revealed that TLR4 displayed a diffuse spotty
distribution in the cytoplasm in HepG2.2.15 cells, and HBx had a similar cytoplasmic staining. b Lysates of HepG2.2.15 cells were immunoprecipitated with
anti-HBx antibody and TLR4 protein was examined using Western blot analysis. TLR4 was detected in the immunoprecipitated HBx complex, but not in
the IgG control sample. P< 0.05
Wang et al. BMC Cancer  (2015) 15:821 Page 7 of 9
between TLR4 and HBx, HBx was immunoprecipitated
from HepG2.2.15 cells using anti-HBx monoclonal
antibody and then subjected to Western blot analysis
for the presence of TLR4. As shown in Fig. 6b, TLR4
was detected in the immunoprecipitated HBx com-
plex, but not in the IgG control sample.
Discussion
TLR4 is dysregulated in many human cancers, such as
gastric cancer [17], colorectal cancer [18], and non-small
cell lung cancer (NSCLC) [19]. Pathogenic stimulation is
an important factor in modulating the expression of
TLRs in cancer cells. For instance, Wang et al. [20] re-
ported that Helicobacter pylori infection regulates TLR4
expression during gastric carcinogenesis. It has been
documented that the expression of TLR4 is increased in
HBV-related cirrhosis and HCC [21]. Wang et al. [22]
showed that transfection of HK-2 cells, an immortalized
proximal tubule epithelial cell line, with HBx gene re-
sults in upregulation of TLR4. Consistently, our data
found that compared to the other HCC cell lines studied,
HBV-related HepG2.2.15 cells had greater mRNA and
protein levels of TLR4. These findings suggest that TLR4
expression is regulated in HCC cells at least partially by
HBV infection, largely at the transcriptional level.
Accumulating evidence indicates that dysregulation of
TLR4 is causally linked to tumor development and
growth. TLR4 silencing has been found to suppress
human NSCLC cell growth [19]. Yuan et al. [23] re-
ported that activation of TLR4 signaling promotes gas-
tric cancer progression by inducing the production of
mitochondrial reactive oxygen species and subsequent
activation of Akt and NF-κB signaling [23]. In contrast,
constitutively active TLR4 was found to reduce tumor
load in an APC (Min/+) mouse model of colorectal
carcinoma through induction of apoptosis [24]. These
studies suggest that TLR4 plays a complex role in tumor
development and progression. Our data revealed that
TLR4 downregulation decreased the proliferation and
induced cell cycle arrest and apoptosis in HepG2.2.15
cells, indicating its requirement for HBV-related HCC
cell survival and growth. In vivo studies confirmed the
mediating role of TLR4 in HBV-related HCC tumor
growth. TLR4 downregulation may have a specific role
in limiting the progression of HBV-related tumor, while
HBV-unrelated HepG2 cells cause tumor development in
nude mice with or without TLR4 downregulation. In agree-
ment with our findings, Dapito et al. [25] demonstrated
that TLR4 signaling is implicated in HCC progression, me-
diating increased proliferation and prevention of apoptosis.
HBx plays a critical role in HBV-related HCC patho-
genesis [5]. Our biochemical studies revealed a physical
interaction between TLR4 and HBx in HepG2.2.15
cells, which may account for the tumor-promoting
effects of TLR4 in HBV-related HCC cells. HBx protein
is capable of regulating several intracellular signaling
pathways, such as NF-κB and MAPKs [26, 27]. Interest-
ingly, we found that TLR4 downregulation interfered
with the activation of ERK1/2, but not JNK1/2, p38, or
NF-κB. Moreover, the effect of TLR4 silencing o
HepG2.2.15 cell growth was approximately phenocop-
ied by chemical inhibition of ERK1/2. However, inhib-
ition of JNK1/2, p38, or NF-κB activity had no
analogous influence on HepG2.2.15 cell growth. Taken
together, our data suggest that the effect of TLR4 on
HBV-related HCC cell proliferation is at least partially
mediated through regulation of ERK1/2 activation.
Since HBx has been shown to induce phosphorylation
of ERK1/2 and promote the proliferation of liver cells
[28], the interaction between TLR4 and HBx may be in-
volved in the regulation of ERK1/2 activation in HCC
cells by TLR4.
However, we have to admit that NF-κB and MAPKs
are limited research pathways. ERK1/2 may be the con-
cerned signaling, and it shall not be the only one. In the
future we will further investigate the possible pathways
of TLR4 involved in HCC, and its relationship with
HBx. Although HepG2.2.15 cell is just a single HBV-
related cell line, its mRNA and protein expression level is
highest among all 5 cell lines. Besides that, HepG2.2.15
cell carries HBV. Therefore, HepG2.2.15 cell has sufficient
characteristics and representativeness for the research.
We are conscious that if more cell lines are investigated,
then as a result more sufficient evidence can certainly be
provided to our experiement. We wish to achieve this in
the upcoming experiments. Additionally, to further im-
prove the accuracy of the experiments, we plan to upregu-
late TLR4 as positive treatment in the future.
Conclusions
Our data show that TLR4 is required for the growth and
survival of HBV-related HCC cells, which is mediated, at
least partially, through ERK1/2 signaling. The interaction
between TLR4 and HBx may be involved in the regulation
of ERK1/2 activation by TLR4. TLR4 may thus represent a
therapeutic target for HCC, especially HBV-related HCC.
Abbreviations
BSA: bovine serum albumin; CCK8: cell counting kit-8; DAPI: 4′,6-diamidino −2-
phenylindole; DMEM: Dulbecco’s modified Eagle’s medium; HBV: hepatitis B virus;
HBx: HBV X protein; HCC: hepatocellular carcinoma; LPS: lipopolysaccharide;
MAPKs: mitogen-activated protein kinases; NSCLC: non-small cell lung cancer;
PDTC: pyrrolidine dithiocarbamate; PMSF: phenylmethylsulfonyl fluoride;
qPCR: Quantitative Real-Time Polymerase Chain Reaction; siRNAs: small interfering
RNAs; TLR4: toll-like receptor 4.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YW carried out the molecular genetic studies, participated in the sequence
alignment and drafted the manuscript. YO, DX and ZZ carried out the
Wang et al. BMC Cancer  (2015) 15:821 Page 8 of 9
biological functions. XZ, YC and WY participated in the detection of
signaling. JC and LH participated in the design of the study and performed
the statistical analysis. AL conceived of the study, and participated in its
design and coordination and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported in part by grants from National Nature Science
Foundation of China (No. 81160305) to Anwen Liu.
Received: 28 January 2015 Accepted: 27 October 2015
References
1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and
molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.
2. Ferlay J. Globocan 2012: estimated cancer incidence, mortality and prevalence
worldwide in 2012. iarc cancerbase, IARC, Lyon, France. http://globocan.iarc.fr/
Pages/fact_sheets_cancer.aspx. Accessed 16 June 2014
3. Xu C, Zhou W, Wang Y, Qiao L. Hepatitis B virus-induced hepatocellular
carcinoma. Cancer Lett. 2014;345(2):216–22.
4. Su IJ, Wang HC, Wu HC, Huang WY. Ground glass hepatocytes contain pre-S
mutants and represent preneoplastic lesions in chronic hepatitis B virus
infection. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1169–74.
5. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B
virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26
Suppl 1:144–52.
6. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem
Biophys Res Commun. 2009;388(4):621–5.
7. Gaudreault E, Fiola S, Olivier M, Gosselin J. Epstein-Barr virus induces MCP-1
secretion by human monocytes via TLR2. J Virol. 2007;81(15):8016–24.
8. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, et al. Toll-like
receptor-mediated control of HBV replication by nonparenchymal liver cells
in mice. Hepatology. 2007;46(6):1769–78.
9. Uno K, Kato K, Atsumi T, Suzuki T, Yoshitake J, Morita H, et al. Toll-like
receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter
pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am
J Physiol Gastrointest Liver Physiol. 2007;293(5):G1004–12.
10. Luddy KA, Robertson-Tessi M, Tafreshi NK, Soliman H, Morse DL. The role of
toll-like receptors in colorectal cancer progression: evidence for epithelial to
leucocytic transition. Front Immunol. 2014;5:429.
11. Rich AM, Hussaini HM, Parachuru VP, Seymour GJ. Toll-like receptors and
cancer, particularly oral squamous cell carcinoma. Front Immunol. 2014;5:464.
12. Jing YY, Han ZP, Sun K, Zhang SS, Hou J, Liu Y, et al. Toll-like receptor 4
signaling promotes epithelial-mesenchymal transition in human
hepatocellular carcinoma induced by lipopolysaccharide. BMC Med.
2012;10:98.
13. Wang Z, Yan J, Lin H, Hua F, Wang X, Liu H, et al. Toll-like receptor 4 activity
protects against hepatocellular tumorigenesis and progression by regulating
expression of DNA repair protein Ku70 in mice. Hepatology.
2013;57(5):1869–81.
14. Wang L, Zhu R, Huang Z, Li H, Zhu H. Lipopolysaccharide-induced toll-like
receptor 4 signaling in cancer cells promotes cell survival and proliferation
in hepatocellular carcinoma. Dig Dis Sci. 2013;58(8):2223–36.
15. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition
receptors and their cross talk. Annu Rev Biochem. 2007;76:447–80.
16. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human
diseases. Biochim Biophys Acta. 2010;1802(4):396–405.
17. Fernandez-Garcia B, Eiro N, Gonzalez-Reyes S, Gonzalez L, Aguirre A, Gonzalez
LO, et al. Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer.
J Immunother. 2014;37(2):77–83.
18. Sussman DA, Santaolalla R, Bejarano PA, Garcia-Buitrago MT, Perez MT,
Abreu MT, et al. In silico and Ex vivo approaches identify a role for toll-like
receptor 4 in colorectal cancer. J Exp Clin Cancer Res. 2014;33:45.
19. Li D, Jin Y, Sun Y, Lei J, Liu C. Knockdown of toll-like receptor 4 inhibits
human NSCLC cancer cell growth and inflammatory cytokine secretion in
vitro and in vivo. Int J Oncol. 2014;45(5):813–21.
20. Wang TR, Peng JC, Qiao YQ, Zhu MM, Zhao D, Shen J, et al. Helicobacter
pylori regulates TLR4 and TLR9 during gastric carcinogenesis. Int J Clin Exp
Pathol. 2014;7(10):6950–5.
21. Soares JB, Pimentel-Nunes P, Afonso L, Rolanda C, Lopes P, Roncon-
Albuquerque R, et al. Increased hepatic expression of TLR2 and TLR4 in
the hepatic inflammation-fibrosis- carcinoma sequence. Innate Immun.
2012;18(5):700–8.
22. Wang X, Zhou Y, Zhu N, Yuan WJ. Effects of hepatitis B virus X gene on
apoptosis and expression of immune molecules of human proximal tubular
epithelial cells. Arch Virol. 2013;158(12):2479–85.
23. Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4
signaling promotes gastric cancer progression by inducing mitochondrial
ROS production. Cell Death Dis. 2013;4, e794.
24. Li Y, Teo WL, Low MJ, Meijer L, Sanderson I, Pettersson S, et al. Constitutive
TLR4 signalling in intestinal epithelium reduces tumor load by increasing
apoptosis in APC(Min/+) mice. Oncogene. 2014;33(3):369–77.
25. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al.
Promotion of hepatocellular carcinoma by the intestinal microbiota and
TLR4. Cancer Cell. 2012;21(4):504–16.
26. Guan J, Chen XP, Zhu H, Luo SF, Cao B, Ding L. Involvement of extracellular
signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug
resistance induced by HBx in hepatoma cell line. World J Gastroenterol.
2004;10(23):3522–7.
27. Fan H, Yan X, Zhang Y, Zhang X, Gao Y, Xu Y, et al. Increased expression of
Gp96 by HBx-induced NF-kappaB activation feedback enhances hepatitis B
virus production. PLoS One. 2013;8(6), e65588.
28. Shan C, Xu F, Zhang S, You J, You X, Qiu L, et al. Hepatitis B virus X protein
promotes liver cell proliferation via a positive cascade loop involving
arachidonic acid metabolism and p-ERK1/2. Cell Res. 2010;20(5):563–75.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wang et al. BMC Cancer  (2015) 15:821 Page 9 of 9
